These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 2569218)

  • 21. Behavioural responses to the selective D1-dopamine receptor agonist R-SK&F 38393 and the selective D2-agonist RU 24213 in young compared with aged rats.
    Molloy AG; Waddington JL
    Br J Pharmacol; 1988 Oct; 95(2):335-42. PubMed ID: 2906555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential effects of dopamine D-1 and D-2 receptor agonists on EEG activity and behaviour in the rabbit.
    Ongini E; Caporali MG
    Neuropharmacology; 1987 Apr; 26(4):355-60. PubMed ID: 2953987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Permissive role of D-1 receptor stimulation for the expression of D-2 mediated behavioral responses: a quantitative phenomenological study in rats.
    Longoni R; Spina L; Di Chiara G
    Life Sci; 1987 Nov; 41(18):2135-45. PubMed ID: 2959833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dopamine D-1 but not D-2 receptor stimulation of the dorsal striatum potentiates apomorphine-induced jaw movements in rats.
    Koshikawa N; Tomiyama K; Omiya K; de Beltrán KK; Kobayashi M
    Eur J Pharmacol; 1990 Mar; 178(2):189-94. PubMed ID: 1970305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Obligatory D-1/D-2 receptor interaction in the generation of dopamine agonist related behaviors.
    Braun AR; Chase TN
    Eur J Pharmacol; 1986 Nov; 131(2-3):301-6. PubMed ID: 3493161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Responses to selective D-1 and D-2 agonists after repeated treatment with selective D-1 and D-2 antagonists.
    Gandolfi O; Dall'olio R; Vaccheri A; Roncada P; Montanaro N
    Pharmacol Biochem Behav; 1988 Jun; 30(2):463-9. PubMed ID: 3262877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of dopamine D-1 and D-2 receptors in the ventral striatum in the turning behaviour of rats.
    Koshikawa N; Mori E; Maruyama Y; Yatsushige N; Kobayashi M
    Eur J Pharmacol; 1990 Mar; 178(2):233-7. PubMed ID: 1970306
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are the catecholestrogens involved in estrogen-induced striatal dopamine receptor supersensitivity?
    Ferretti C; Ghi P; Blengio M; Gaietta G; Barrera G; Genazzani E
    Eur J Pharmacol; 1989 Jul; 166(2):149-56. PubMed ID: 2551698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of dopamine D-1 and D-2 receptor selective drugs on dopamine release and metabolism in rat striatum in vivo.
    Zetterström T; Sharp T; Ungerstedt U
    Naunyn Schmiedebergs Arch Pharmacol; 1986 Oct; 334(2):117-24. PubMed ID: 2946964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alkylation of striatal dopamine receptors abolishes stereotyped behavior but has no effect on dopamine stimulated adenylate cyclase activity.
    Cameron DL; Crocker AD
    Neurosci Lett; 1988 Jul; 90(1-2):165-71. PubMed ID: 3045699
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ontogenetic differences in the effects of EEDQ on dopamine-mediated behaviors.
    Mestlin M; McDougall SA
    Pharmacol Biochem Behav; 1993 Aug; 45(4):797-802. PubMed ID: 8105488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Locomotor behaviors in response to new selective D-1 and D-2 dopamine receptor agonists, and the influence of selective antagonists.
    Molloy AG; O'Boyle KM; Pugh MT; Waddington JL
    Pharmacol Biochem Behav; 1986 Jul; 25(1):249-53. PubMed ID: 3529126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced behavioral stereotypies elicited by intrastriatal injection D1 and D2 dopamine agonists in intact rats.
    Bordi F; Meller E
    Brain Res; 1989 Dec; 504(2):276-83. PubMed ID: 2574622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synergistic blockade of some dopamine-mediated behaviours by (-)-sulpiride and SCH 23390 in the rat.
    Dall'Olio R; Roncada P; Vaccheri A; Gandolfi O; Montanaro N
    Psychopharmacology (Berl); 1989; 98(3):342-6. PubMed ID: 2568655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 7-[3-(4-[2,3-Dimethylphenyl]piperazinyl)propoxy]-2(1H)-quinolinone (OPC-4392), a presynaptic dopamine autoreceptor agonist and postsynaptic D2 receptor antagonist.
    Yasuda Y; Kikuchi T; Suzuki S; Tsutsui M; Yamada K; Hiyama T
    Life Sci; 1988; 42(20):1941-54. PubMed ID: 3130534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SCH 23390 may alter dopamine-mediated motor behaviour via striatal D-1 receptors.
    Boyce S; Kelly E; Davis A; Fleminger S; Jenner P; Marsden CD
    Biochem Pharmacol; 1985 May; 34(10):1665-9. PubMed ID: 2988552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective blockade of dopamine D-1 receptor by SCH 23390 affects dopamine agonist binding to 3H-spiperone labeled D-2 receptors in rat striatum.
    Zhang X; Segawa T
    Jpn J Pharmacol; 1989 Jul; 50(3):333-45. PubMed ID: 2569545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective D2 dopamine receptor agonists prevent catalepsy induced by SCH 23390, a selective D1 antagonist.
    Meller E; Kuga S; Friedhoff AJ; Goldstein M
    Life Sci; 1985 May; 36(19):1857-64. PubMed ID: 3157851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Central dopaminergic properties of HW-165 and its enantiomers; trans-octahydrobenzo(f)quinoline congeners of 3-PPP.
    Hjorth S; Svensson K; Carlsson A; Wikström H; Andersson B
    Naunyn Schmiedebergs Arch Pharmacol; 1986 Jul; 333(3):205-18. PubMed ID: 3762735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
    Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A
    J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.